The Belgian UCB exits the primary care market in the United States, to focus on specialist therapeutic areas such as immunology and neurology. The decision will be effective as of March 1, 2010.
The company will therefore transfer commercial responsibility for some of its 'generalist' products to other companies: the anti-allergy Xyzal will pass to Sanofi-aventis and the anti-asthma ProAir HFA to Teva.
Instead, it will continue to support the promotion of the anti-tussive Tussionex. "We are deeply grateful to the American primary care team - comments the president of UCB North America, Greg Duncan - because its ten-year work has strengthened the company's position and success".
PharmaKronos – 03 February 2010
